Allurion Technologies (ALUR) shares surged more than 81% premarket Friday after the company said overnight that it plans to initiate a combination clinical study to improve muscle mass and overall body composition.
The clinical trial will combine the Allurion Program, a weight-loss platform, with GLP-1 agonists. The latter are primarily used to manage Type 2 diabetes and obesity.
The study aims to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can "lose significant weight while increasing muscle mass and improving overall body composition," Allurion Chief Executive Shantanu Gaur said late Thursday.
Price: 6.73, Change: +3.03, Percent Change: +81.89
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。